Quantitative characterization of platelet count and alanine aminotransferase dynamics to inform personalized dosing in the first-in-human LP-184 trial
Cancer Chemotherapy and Pharmacology · 12.08.2026 · 96 (1)
DOI: 10.1007/s00280-026-04937-2 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 12.08.2026. Verfasst von Jianli Zhou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Lantern Pharma Inc., Plano, TX, 75024, USA. Hauptthemen laut MEDLINE: Alanine Transaminase, Antineoplastic Agents. Die Arbeit nennt 19 Literaturangaben. Gefördert von: Lantern Pharma Inc..
Abstract (Originalsprache)
PURPOSE: Safety evaluation in first-in-human (FIH) Phase 1 oncology trials is largely descriptive and provides limited quantitative insights. This study characterized the dynamics of platelet count (PLT) and alanine aminotransferase (ALT) concentration in the LP-184 FIH study and explored statistical modeling to support personalized dosing strategies. METHODS: PLT and ALT data were analyzed to characterize temporal trends, inter-patient variability, and correlations with baseline characteristics and exposure. Firth logistic regression was fitted to identify potential contributors to clinically relevant PLT abnormalities. RESULTS: PLT nadir predominantly occurred in cycle 2, with baseline PLT and total single-infusion dose as critical contributors. Patients with baseline PLT below 200 K/µL were at high risk of developing grade ≥ 2 PLT decreased adverse events. ALT levels mostly peaked in cycle 1, with a moderate association with dose and no evident relationship to baseline liver metastases. Patients with glioblastoma exhibited a higher probability of experiencing ALT increased events at grade ≥ 2. A single infusion dose above 40 mg was associated with increased occurrence of high-grade PLT decreased and ALT increased events. A personalized dose recommendation strategy is proposed. CONCLUSION: Integration of in-depth data analytics in FIH studies facilitates earlier safety signal detection and informs safety monitoring and dose selection in later studies. REGISTRY: ClinicalTrials.gov, TRN: NCT05933265, Registration date: 23 June 2023.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lantern Pharma Inc., Plano, TX, 75024, USA.
- Mays Cancer Center, University of Texas Health San Antonio, San Antonio, TX, 78229, USA.
- Lantern Pharma Inc., Plano, TX, 75024, USA. rewesuedo@lanternpharma.com.
Förderung
- Lantern Pharma Inc.
Zitieren
APA
Zhou, J., Mahadevan, D., Parekh, J., Chamberlain, M., Bhatia, K., & Ewesuedo, R. (2026). Quantitative characterization of platelet count and alanine aminotransferase dynamics to inform personalized dosing in the first-in-human LP-184 trial. Cancer Chemotherapy and Pharmacology, 96(1). https://doi.org/10.1007/s00280-026-04937-2
Vancouver
Zhou J, Mahadevan D, Parekh J, Chamberlain M, Bhatia K, Ewesuedo R. Quantitative characterization of platelet count and alanine aminotransferase dynamics to inform personalized dosing in the first-in-human LP-184 trial. Cancer Chemotherapy and Pharmacology. 2026;96(1). doi:10.1007/s00280-026-04937-2
BibTeX
@article{Zhou2026,
author = {Zhou, Jianli and Mahadevan, Daruka and Parekh, Jay and Chamberlain, Marc and Bhatia, Kishor and Ewesuedo, Reginald},
title = {Quantitative characterization of platelet count and alanine aminotransferase dynamics to inform personalized dosing in the first-in-human LP-184 trial},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2026},
volume = {96},
number = {1},
doi = {10.1007/s00280-026-04937-2}
}
EUVIMED